Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)

Abstract: Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients aged ≥65 years. In this fi...

Full description

Saved in:
Bibliographic Details
Main Authors: Chong Chyn Chua, Sun Loo, Chun Yew Fong, Stephen B. Ting, Ing Soo Tiong, Shaun Fleming, Natasha S. Anstee, Adam Ivey, Michael Ashby, Tse-Chieh Teh, John Reynolds, Andrew W. Roberts, Andrew H. Wei
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925000345
Tags: Add Tag
No Tags, Be the first to tag this record!